Inbeeo’s Post

🎉 Happy birthday Inizio 🎂 We know, you know, most of our agencies are over 30 years old!... 😉 Yet the Inizio brand, the fact that we have consolidated under ONE the constellations of our agencies, is 2 years old 💥 And we are a launch powerhouse!!!! ✅ 50% of all product launches in the last 2 years have been supported by Inizio ✅ 95% of the top performing products were launched in [partnership with Inizio ✅ >40% of Inizio-supported assets are projected to be blockbuster products Read move about our latest capabilities below 👇 🥂 Proud to celebrate this incredible milestone with all of you. #ReimagineHealth #Healthcare #Pharma #Commercialization

More happy news on a Monday...it's our second birthday! 🎂 Ashfield, part of UDG Healthcare (now Inizio) and Huntsworth Health (now Inizio) came together two years ago, on 30th June, to become #inizio. A global pharmaceutical commercialisation partner, made up of four distinct divisions of Inizio Advisory, Inizio Medical, Inizio Engage (that's me 🙋♀️ ) and Inizio Evoke. We have achieved so much in two years - check it out below ⬇ We have such a rich and diverse set of capabilities across the 12,000 of us spread over 50 markets globally 🌎 From the deeply scientific and evidence-driven, to the ingeniously creative and experiential; from the external customer and stakeholder landscape, to the internal employee and shareholder landscape. If you're curious and wondering who we are, and what we do - get in touch, happy to have a virtual coffee to explain more ☕ #ReimagineHealth #ConnectedCapabilities #Commercialization #ProductLaunch #CustomerEngagement #EmployeeEngagement #Experience #Design #HappyBirthday #Anniversary #Pharma #Pharmaceuticals #BioPharma #LifeSciences

🧬 𝐅𝐚𝐜𝐢𝐧𝐠 𝐛𝐨𝐭𝐭𝐥𝐞𝐧𝐞𝐜𝐤𝐬 𝐨𝐟 𝐂𝐀𝐑-𝐓 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 Since the first approval of CAR-T in 2017, six products have made it to the U.S. market to treat various blood cancers. Despite their great efficacy and rapid growth trajectory, CAR-T therapies still face several challenges: ⚆ Healthcare infrastructure - Hospitals face significant challenges in expanding their infrastructure to accommodate the complex needs of CAR-T therapy patients and to address side effects ⚆ Human resources - Delivering CAR-T to patients requires a specialized, multidisciplinary team of healthcare professionals, which is challenging due to shortages (especially of nurses) and overall burnout within the sector ⚆ Financial and operational efficiency - Money, money, money. Let's not forget about the costs of CAR-T. These treatments are expensive and complex to manufacture, which makes it difficult to plan and efficiently deliver CAR-T to patients 𝘏𝘰𝘸 𝘤𝘢𝘯 𝘵𝘩𝘦𝘴𝘦 𝘭𝘪𝘮𝘪𝘵𝘢𝘵𝘪𝘰𝘯𝘴 𝘣𝘦 𝘰𝘷𝘦𝘳𝘤𝘰𝘮𝘦? More info: https://lnkd.in/dzhwdRdr #cart #celltherapy #oncology #pharma #drugdiscovery #innovation #drjojo

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP

In this article, my Foley colleague, Antoinette Konski, discusses how CAR-T therapy has significantly reduced its manufacturing time from 37 days to 14 days due to improved manufacturing processes. These developments are promising for patients and the health care industry as a whole. Click below to read more. #HealthCare #Pharma #Manufacturing #IP